Kaposi's Sarcoma-Associated Herpesvirus Reactivation by Targeting of a dCas9-Based Transcription Activator to the ORF50 Promoter.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
27 08 2020
Historique:
received: 03 07 2020
revised: 15 08 2020
accepted: 24 08 2020
entrez: 2 9 2020
pubmed: 2 9 2020
medline: 9 3 2021
Statut: epublish

Résumé

CRISPR activation (CRISPRa) has revealed great potential as a tool to modulate the expression of targeted cellular genes. Here, we successfully applied the CRISPRa system to trigger the Kaposi's sarcoma-associated herpesvirus (KSHV) reactivation in latently infected cells by selectively activating ORF50 gene directly from the virus genome. We found that a nuclease-deficient Cas9 (dCas9) fused to a destabilization domain (DD) and 12 copies of the VP16 activation domain (VP192) triggered a more efficient KSHV lytic cycle and virus production when guided to two different sites on the ORF50 promoter, instead of only a single site. To our surprise, the virus reactivation induced by binding of the stable DD-dCas9-VP192 on the ORF50 promoter was even more efficient than reactivation induced by ectopic expression of ORF50. This suggests that recruitment of additional transcriptional activators to the ORF50 promoter, in addition to ORF50 itself, are needed for the efficient virus production. Further, we show that CRISPRa can be applied to selectively express the early lytic gene, ORF57, without disturbing the viral latency. Therefore, CRISPRa-based systems can be utilized to facilitate virus-host interaction studies by controlling the expression of not only cellular but also of specific KSHV genes.

Identifiants

pubmed: 32867368
pii: v12090952
doi: 10.3390/v12090952
pmc: PMC7552072
pii:
doi:

Substances chimiques

Capsid Proteins 0
Immediate-Early Proteins 0
Recombinant Fusion Proteins 0
Rta protein, Human herpesvirus 8 0
Trans-Activators 0
VP19 protein, Human herpesvirus 1 0
CRISPR-Associated Protein 9 EC 3.1.-
Cas9 endonuclease Streptococcus pyogenes EC 3.1.-

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Virol. 2003 Jan;77(2):1441-51
pubmed: 12502859
Nat Methods. 2016 Jul;13(7):563-567
pubmed: 27214048
J Virol Methods. 2011 Jun;174(1-2):12-21
pubmed: 21419799
Bioinformatics. 2018 Sep 1;34(17):i884-i890
pubmed: 30423086
Cancer Res. 2020 Aug 1;80(15):3116-3129
pubmed: 32518203
Clin Infect Dis. 2010 Aug 1;51(3):350-8
pubmed: 20583924
Stem Cell Reports. 2015 Sep 8;5(3):448-59
pubmed: 26352799
Cancer Res. 2020 Aug 1;80(15):3130-3144
pubmed: 32518204
Science. 1994 Dec 16;266(5192):1865-9
pubmed: 7997879
Cell Host Microbe. 2011 Dec 15;10(6):577-90
pubmed: 22177562
J Virol. 1999 Nov;73(11):9348-61
pubmed: 10516043
Bioinformatics. 2014 Apr 1;30(7):923-30
pubmed: 24227677
Nat Methods. 2015 Apr;12(4):326-8
pubmed: 25730490
Virology. 2004 Aug 1;325(2):225-40
pubmed: 15246263
Blood. 1995 Aug 15;86(4):1276-80
pubmed: 7632932
J Virol. 2016 Dec 16;91(1):
pubmed: 27795414
Chem Biol. 2010 Sep 24;17(9):981-8
pubmed: 20851347
Virology. 1998 Dec 20;252(2):304-12
pubmed: 9878608
Semin Cancer Biol. 2014 Jun;26:69-77
pubmed: 24486643
Nat Biotechnol. 2019 Aug;37(8):907-915
pubmed: 31375807
PLoS Pathog. 2012 Jan;8(1):e1002479
pubmed: 22253595
Cell Host Microbe. 2013 Apr 17;13(4):429-40
pubmed: 23601105
J Virol. 2004 Jun;78(12):6585-94
pubmed: 15163750
N Engl J Med. 1995 May 4;332(18):1186-91
pubmed: 7700311
Cell. 2013 Feb 28;152(5):1173-83
pubmed: 23452860
J Virol. 2007 Dec;81(24):13299-314
pubmed: 17913801
Cell. 2013 Jul 18;154(2):442-51
pubmed: 23849981
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Nat Med. 1996 Mar;2(3):342-6
pubmed: 8612236
J Virol. 2003 Apr;77(7):4205-20
pubmed: 12634378
J Pathol. 2015 Jan;235(2):368-80
pubmed: 25212381
Science. 2012 Aug 17;337(6096):816-21
pubmed: 22745249
Cell. 2014 Oct 23;159(3):647-61
pubmed: 25307932
Genes Dev. 2002 Aug 1;16(15):1977-89
pubmed: 12154127
Nat Commun. 2018 Jul 6;9(1):2643
pubmed: 29980666
J Virol. 2012 Sep;86(18):9708-20
pubmed: 22740391
J Virol. 1997 Jan;71(1):314-24
pubmed: 8985352
Clin Infect Dis. 2012 Feb 1;54(3):424-33
pubmed: 22095568
Curr Opin Virol. 2017 Oct;26:156-162
pubmed: 29031103
Genome Biol. 2006;7(10):R100
pubmed: 17076895

Auteurs

Endrit Elbasani (E)

Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.

Francesca Falasco (F)

Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.

Silvia Gramolelli (S)

Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.

Veijo Nurminen (V)

Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.

Thomas Günther (T)

Heinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany.

Jere Weltner (J)

Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.

Diego Balboa (D)

Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.

Adam Grundhoff (A)

Heinrich Pette Institute, Leibniz Institute for Experimental Virology, 20251 Hamburg, Germany.

Timo Otonkoski (T)

Stem Cells and Metabolism Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.

Päivi M Ojala (PM)

Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.
Department of Infectious Diseases, Imperial College London, London W2 1NY, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH